Affiliation:
1. School of Integrative Biological and Chemical Sciences, College of Sciences, The University of Texas Rio Grande Valley, Edinburg, TX 78539, USA
Abstract
Glioblastoma is most commonly a primary brain tumor and the utmost malignant one, with a survival rate of approximately 12–18 months. Glioblastoma is highly heterogeneous, demonstrating that different types of cells from the same tumor can manifest distinct gene expression patterns and biological behaviors. Conventional therapies such as temozolomide, radiation, and surgery have limitations. As of now, there is no cure for glioblastoma. Alternative treatment methods to eradicate glioblastoma are discussed in this review, including targeted therapies to PI3K, NFKβ, JAK-STAT, CK2, WNT, NOTCH, Hedgehog, and TGFβ pathways. The highly novel application of oncolytic viruses and nanomaterials in combating glioblastoma are also discussed. Despite scores of clinical trials for glioblastoma, the prognosis remains poor. Progress in breaching the blood–brain barrier with nanomaterials and novel avenues for targeted and combination treatments hold promise for the future development of efficacious glioblastoma therapies.
Funder
National Institute of General Medical Sciences
Reference156 articles.
1. Rising Incidence of Glioblastoma Multiforme in a Well-Defined Population;Grech;Cureus,2020
2. Glioblastoma multiforme: State of the art and future therapeutics;Wilson;Surg. Neurol. Int.,2014
3. Chen, C., Xu, H., Song, K., Zhang, Y., Zhang, J., Wang, Y., Sheng, X., Chen, L., and Qin, Z. (2022). Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center. J. Clin. Med., 11.
4. Temozolomide resistance in glioblastoma multiforme;Lee;Genes Dis.,2016
5. Mechanisms of temozolomide resistance in glioblastoma—A comprehensive review;Singh;Cancer Drug Resist.,2021
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献